Visibility in the media.
Stay informed with the latest press releases, media coverage, and corporate milestones shaping the future of retinal imaging.
See more news.
Uncover a world of information.
Access the latest on the evolution of retinal AI in healthcare.
Featured FAQs.
Direct answers to the most critical questions regarding our technology’s financial, technical, and clinical implementation.
The EyeArt system is FDA-cleared for use in adults who have been diagnosed with diabetes but have not been previously diagnosed with more than mild diabetic retinopathy. It is intended for use in frontline healthcare settings by trained professionals.
The EyeArt system is FDA-cleared for the autonomous detection of both more than mild and vision-threatening diabetic retinopathy in adults with diabetes. These thresholds provide clinicians the actionable data to prioritize referrals for high-risk patients.
Yes. In the US, providers can utilize CPT code 92229 for point of care autonomous retinal imaging with an AI-generated report. This code has an established national Medicare price, which helps health systems offset implementation costs and support long-term program growth.
See all of our FAQs.